Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365405 | 0.90 | MAPK14 (0.41) | PDK2MAPK14NPC1RAB9AIL2 | |
| SCHEMBL12364995 | 0.90 | PDK2 (0.45) | PDK2MAPK14NPC1RAB9AIL2 | |
| SCHEMBL12365674 | 0.89 | IL2 (0.43) | PDK2MAPK14NPC1RAB9AIL2 | |
| SCHEMBL12390275 | 0.88 | PDK2 (0.42) | PDK2MAPK14NPC1RAB9AIL2 | |
| SCHEMBL12365424 | 0.88 | MAPK14 (0.41) | PDK2MAPK14ALDH1A1 | |
| SCHEMBL12365419 | 0.87 | MAPK14 (0.43) | PDK2MAPK14NPC1RAB9AIL2 | |
| SCHEMBL12365807 | 0.87 | MAPK14 (0.47) | PDK2MAPK14IL2KMT2AMEN1 | |
| SCHEMBL12365869 | 0.86 | SRD5A2 (0.43) | PDK2MAPK14ALDH1A1 | |
| SCHEMBL12365958 | 0.86 | MAPK14 (0.39) | PDK2MAPK14NPC1RAB9AIL2 | |
| SCHEMBL12365832 | 0.85 | MAPK14 (0.44) | PDK2MAPK14NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PDK2 3920/4885MAPK14 3304/4885NPC1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.